Vagus Nerve Stimulation in Failed Epilepsy Surgery: 36 Month Outcomes From the CORE-VNS Study

ObjectiveVagus nerve stimulation (VNS) is an established neuromodulation therapy used in the management of drug-resistant epilepsy (DRE), or when other intracranial surgical modalities have not reduced seizure burden. We evaluated whether prior intracranial surgery for epilepsy influences safety and effectiveness outcomes with adjunctive VNS, using real-world data from the CORE-VNS study. MethodsCORE-VNS (NCT03529045), a prospective, multicenter, international observational study, was designed to collect data on seizure and non-seizure outcomes in patients with DRE treated with VNS. Participants were identified as having or not having undergone prior intracranial brain surgery for epilepsy (ICSE) and received an initial VNS implant. Baseline seizure frequency data and patient-reported outcome measures were collected at 3, 6, 12, 24, and 36 months. This analysis compared the baseline data for VNS therapy and safety outcomes at 36 months. ResultsAmong 531 participants implanted with VNS, prior ICSE was performed in 84. Median percentage seizure reductions at 36 months for all seizures (76.6% and 76.3%), all focal seizures (83.3% and 71.8%), and all generalized seizures (77.8% and 76.2%) were found to be similar between those without and with a history of ICSE, respectively. The 50% responder rate for all seizures reported at baseline was similar, 64.8% and 61.8%, in both groups and complete seizure freedom was reported by 17.9% and 8.8%, respectively. Implant-related adverse events (AE) and serious AE rates were similar between groups. ConclusionVNS was associated with clinically meaningful seizure reductions and showed a consistent safety profile irrespective of the history of ICSE. Prior ICSE should not be a contraindication to the consideration of VNS.